{"analyses":[{"ciLowerLimit":"-30.57","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-15.63","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"3.806","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Mean Difference (Final Values)","paramValue":"-23.10","statisticalMethod":"ANCOVA"},{"ciLowerLimit":"-44.24","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-30.89","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"3.447","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Mean Difference (Final Values)","paramValue":"-37.65","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.100","value":"-8.13"},{"groupId":"OG001","spread":"3.157","value":"-31.23"},{"groupId":"OG002","spread":"2.663","value":"-45.79"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"180"},{"groupId":"OG002","value":"278"}],"units":"Participants"}],"description":"The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100, with lower score indicating better health outcomes. Least Squares Mean (LSM) was calculated using analysis of covariance (ANCOVA) with geographic region duration of current episode at baseline (\\< 4 years versus ≥4 years), treatment group, and baseline value in the model.","dispersionType":"Standard Error","groups":[{"description":"Participants received two placebo tablets administered orally QD.","id":"OG000","title":"Placebo Phase 3"},{"description":"Participants received one 2 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain the blind.","id":"OG001","title":"2 mg Baricitinib Phase 3"},{"description":"Participants received one 4 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain the blind.","id":"OG002","title":"4 mg Baricitinib Phase 3"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"All randomized phase 3 participants with non-missing baseline and at least one post-baseline measurement who had evaluable data for this outcome measure.A modified last observation carried forward (mLOCF) imputation technique was used to replace missing data with the most recent non-missing post-baseline assessment.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 36","title":"Percent Change From Baseline in SALT Score - Phase 3","type":"SECONDARY","unitOfMeasure":"percent change"}